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Abstract

Results

The nuclear vitamin D receptor (VDR) modulates gene transcription in
1,25-dihydroxyvitamin D (1,25D) target tissues such as kidney, colon, and
bone. The 1,25D hormone is derived from vitamin D in the skin or from the
diet, and binds to and activates the VDR. We have previously shown that
resveratrol, an antioxidant found in the skin of red grapes, has the ability to
activate the VDR signaling pathway. Moreover, cells treated with both resveratrol and 1,25D resulted in an additive or even synergistic stimulation of
VDR-mediated transcription compared to cells treated with 1,25D alone.
Based on these initial results, experiments were designed to test the significance of mutations in the hormone-binding domain of VDR. Identical hormone treatments were applied to “wild-type” (non-mutated) and single point
VDR mutations. 1,25D displayed a significant drop in activity caused by
these mutations, while the ability of resveratrol to activate VDR was only
modestly attenuated. One possible interpretation of these results is that resveratrol may affect VDR activity indirectly, perhaps via the ability of resveratrol to activate SIRT1, an enzyme which has been shown to deacetylate
(and thereby activate) other nuclear receptors such as the liver X receptor
(LXR). In support of this hypothesis, radiolabeled 1,25D displacement
assays revealed an increase in bound radiolabeled 1,25D only in the presence of resveratrol, suggesting that direct binding of resveratrol to VDR is
unlikely. Additionally, we observed increased transcriptional activity in response to resveratrol in a subset of other nuclear receptors, including the
liver X receptor (LXR), which is closely related to VDR and is known to be
deacetylated by SIRT1. Finally, we tested receptor-mediated transcriptional
activity in a system containing VDR in the absence and presence of overexpressed SIRT1. Transcriptional activity was higher in cells expressing
SIRT1, and synergistic activity of 1,25D combined with resveratrol was observed. We are currently conducting additional experiments employing the
VDR/SIRT1 assay in multiple cellular contexts. In conclusion, this study elucidates, for the first time, a potential novel pathway for "crosstalk" between
two nutritionally derived lipids, vitamin D and resveratrol.

Figures 1.1 – 1.2. Representative experiment investigating the
significance of mutations in the hormone-binding domain of
VDR on receptor activity. Using a VDRE (PER6)-luciferase
reporter assay, identical hormone treatments were applied to cells
transfected with “wild-type” VDR and to VDR with a single mutation
in the hormone-binding pocket (R274L), eliminating the ability of
the receptor to bind to vitamin D. The 57% drop in resveratrol only
activity between WT and mutant R274L VDR (Fig 5.1), compared
to the 98% drop in 1,25D-mediated transcription or the 96% reduction in 1,25D+resveratrol-mediated activity (Fig. 5.2) suggests the
possibility of another pathway for resveratrol action besides direct
binding in the VDR ligand pocket. Similar results were obtained
with another VDR hormone binding mutant (C288G; data not
shown).
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Figure 2. Competitive binding assay. Radiolabeled 1,25D was used to determine if resveratrol
could compete with 1,25D for binding to the vitamin D binding pocket. DHA, a known VDR ligand, was
used as positive control and dexamethasone, a non-VDR ligand was used as a negative control.
When cell lysates containing VDR were treated with increasing concentrations of resveratrol, bound
radiolabeled 1,25D actually increased. This suggests resveratrol may “stabilize” the 1,25D-VDR complex, as opposed to competing with 1,25D for the binding pocket as initially predicted.
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Figures 3.1 - 3.2. Resveratrol induced transcriptional activity in a variety of nuclear receptors. A number of response
elements (ERE, RARE, GRE, RXRE, PXRE, LXRE) in conjunction with a luciferase reporter system were employed to measure nuclear receptor activation by 3.3x10-5 M resveratrol. The
resulting transcriptional activity is described as the fold-effects
over the negative (vehicle) control (not displayed). The cell
lines tested are HCT116 (A) and HEK293 (B).

Background
Figure 3.1

Figure 1. A working model
for transcriptional control
by 1,25D in which (1) the
hormone (1,25D or other
potential ligands such as
resveratrol, indicated by the
red circle) move into the nucleus of the cell and bind
directly to VDR, initiating stimulation of VDR activity. Activated VDR then dimerizes
with a retinoid X receptor
(RXR) and binds to specific
vitamin D responsive elements (VDREs) located in the vicinity of target
genes. Upon activation by 1,25D or other ligand(s), (2) VDR also binds to
coactivators with histone acetyl transferase (HAT) activity, such as SRC-1.
(3) Activated VDR recruits, and delivers to RNA polymerase II, basal
transcription factors such as TFIIB. VDR also binds to D-receptor interacting proteins (DRIPs) which anchor a mediator complex that interacts with
RNA polymerase II. (4) Holo RNA polymerase II acts to initiate the
transcription of vitamin D target genes, some of which are highlighted in red
at the lower right.

Figure 2. A transcriptional
assay (A) measures how
effectively a ligand induces
receptor
activation
and
transcriptional activity. The
responsive element reporter
constructs used to evaluate
resveratrol for receptor-ligand
binding and/or activation
included the vitamin D response elements (VDRE), the
estrogen response element
(ERE), retinoic acid response
element (RARE), glucocorticoid responsive element (GRE), retinoid X
receptor responsive element (RXRE, shown in Fig. 2), pregnane X-receptor
response element (PXRE), and liver X receptor response element (LXRE).
The mammalian two-hybrid assay (B) detects the affinity of the ligand for the
receptor and the ability of the ligand to induce dimerization. This system was
used to test resveratrol modulation of VDR-RXR dimerization (binding of
VDR-AD to RXR-BD), and recruitment of coactivators by VDR-AD, followed
by activation of the luciferase gene (results not shown).

Figure 3.2

Figures 3.3 - 3.4. The potential for synergistic activity between resveratrol and the respective ligands of a variety of
nuclear receptors. The indicated response elements (VDRE,
ERE, RARE, GRE, RXRE, PXRE, LXRE) in conjunction with a
luciferase reporter system were used to measure receptor activation by the respective ligand (in brackets), and any additional
stimulation upon combining the respective ligand with 3.3x10-5
M resveratrol. Ligand concentrations used were 10-6 (ER, GR,
RXR, LXR), 10-7 (RAR, PXR), and 10-9 (VDR). The transcriptional activity is described as fold-effects over the negative control (vehicle).

1,25D and resveratrol are non-competitive activators of the nuclear vitamin
D receptor (VDR). When combined, 1,25D and resveratrol exhibit an additive
or synergistic effect on VDR transactivation.
Resveratrol may function as an indirect activator of the VDR by stimulating
SIRT1, which may consequently lead to SIRT1-mediated modification of
VDR (deacetylation) that causes further stimulation of the receptor.
The indirect activation of VDR via the SIRT1/deacetylation pathway represents a novel form of post-translational regulation of the VDR. The activity
of other nuclear receptors may also be controlled by this pathway.

Future Directions
We will continue to test VDR deacetylation by SIRT1 as follows:



Figure 3.3

Figure 3.4

Figure 4. Evaluation of SIRT1 expression on transcriptional activity induced by 1,25D and resveratrol. HEK293 cells
were transfected with a VDR expression plasmid along with an expression vector for SIRT1 (pSG5-SIRT1) or the empty parent
vector (pSG5) as a negative control. After 24 hours of transfection, the cells were refed with fresh medium containing either
1x10-8 M 1,25D, 2.5x10-5 M resveratrol, a combination of both compounds, or ethanol vehicle. Transcriptional activity was
measured using a Dual-Luciferase Reporter (DLR) Assay system, and reported as normalized relative light units (RLU). Results indicate increased transcriptional activity in the presence of SIRT1 and synergistic activity between 1,25D and
resveratrol.

Figure 4




treating cells with resveratrol (which will activate SIRT1) to determine if
SIRT+resveratrol can stimulate VDR activity in a SIRT-dependent
manner.
transfecting several different cell lines with various amounts of VDR and
SIRT1 to probe the cell-specific effects of SIRT1/resveratrol on VDR
activity.
test the dose response of resveratrol and 1,25D in terms of their
synergistic activation of VDR
evaluate the acetylation status of immunopurified VDR from SIRT1 and
resveratrol treated cells. Since acetylated VDR migrates more slowly
than de-acetylated VDR during SDS-PAGE due to differences in
molecular weight, analysis of VDR immunoprecipitates will allow for the
examination of VDR acetylation status after resveratrol or SIRT1
treatment. We will also employ anti-acetyl-lysine antibodies to probe
the acetylation state of VDR.
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